An analysis of the EMPOWER‐Lung 3 trial found that the addition of cemiplimab to platinum chemotherapy for non–small cell lung cancer (NSCLC) was associated with improved patient quality of life (QOL ...
A chemotherapy-free regimen significantly improved outcomes compared with standard therapy for newly diagnosed Ph+ acute ...
Sacituzumab govitecan and pembrolizumab showed a manageable safety profile in PD-L1–positive metastatic TNBC, with lower dose reduction or discontinuation rates than chemotherapy. The combination ...
For patients with advanced non–small cell lung cancer (NSCLC), regardless of PD-L1 status, cemiplimab plus chemotherapy had favorable survival benefits and patient-reported outcomes over chemotherapy ...
Please provide your email address to receive an email when new articles are posted on . Women with diffuse large B-cell lymphoma experienced significantly longer PFS and OS when receiving chemotherapy ...
Patritumab deruxtecan showed no overall survival benefit over chemotherapy in EGFR mutation-positive NSCLC patients. The drug demonstrated a slight progression-free survival advantage and higher ...
Conducted by Akeso, HARMONi-A Represents the First Statistically Significant OS Benefit Achieved in a Phase III Study by an Ivonescimab-Containing Regimen MIAMI, October 31, 2025--(BUSINESS ...
The phase 3 MajesTEC-3 trial demonstrated that the combination of the bispecific BCMA-directed T-cell engager teclistamab and ...
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the pivotal TROPION-Lung01 Phase III trial showed that datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement ...
A statistically significant improvement in overall survival was observed with the combination vs platinum-based chemotherapy. The Food and Drug Administration (FDA) approved Keytruda ® (pembrolizumab) ...
The Neotorch randomized phase III clinical trial was designed to evaluate whether the addition of perioperative toripalimab [programmed cell death 1 (PD-1) inhibitor] to platinum-based chemotherapy ...
Chemotherapy is the mainstay of treatment for high-risk endometrial carcinoma, and it looks to stay that way, as adding radiation on top does not improve survival over that seen with chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback